Authors: Yinghua Chen Erzhi Gao Liu Yang Xia Liu Kang Li Zhengzhao Liu Caihong Zeng Haitao Zhang Zhihong Liu Weixin Hu
Publish Date: 2016/05/11
Volume: 36, Issue: 7, Pages: 967-974
Abstract
This study aimed to retrospectively analyze the longterm outcome of mycophenolate mofetil MMF therapy for microscopic polyangiitis MPA with mild to moderate renal involvement in Chinese patients Thirtyfour MPA patients 24 females 10 males aged 447 ± 17 years BVAS score 138 ± 32 SCr 22 ± 11 mg/dl with SCr 5 mg/dl and who received glucocorticoids plus MMF therapy for inducing and maintaining remission were included in this study The remission and relapse rates patient and renal survival rates and adverse events were retrospectively analyzed We found that 31 912 of 34 patients achieved remission and were continuously treated with glucocorticoids plus MMF for maintaining remission The median duration of MMF treatment was 24 months IQR 15–53 months and followup time was 86 months IQR 29–124 months During the followup 7 226 patients relapsed one patient died and one patient progressed into endstage renal disease The 5year patient and renal survival rates were 928 and 952 respectively 11 324 patients suffered 16 adverse events 13 of which were pulmonary infection In conclusion glucocorticoids plus MMF regimen as induction and maintenance therapy could achieve high remission rate and good longterm renal survival in MPA patients with mild to moderate renal involvement Prospective controlled trials with a large sample size are needed to confirm the efficacy of MMF in this populationAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards
Keywords: